{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T07:23:09Z","timestamp":1774682589095,"version":"3.50.1"},"reference-count":124,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T00:00:00Z","timestamp":1567555200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"FCT\/FEDER\/COMPETE2020","award":["UID\/BIM\/04501\/2013 and UID\/BIM\/04501\/2019"],"award-info":[{"award-number":["UID\/BIM\/04501\/2013 and UID\/BIM\/04501\/2019"]}]},{"name":"FCT\/FEDER\/COMPETE2020","award":["POCI-01-0247-FEDER-033532"],"award-info":[{"award-number":["POCI-01-0247-FEDER-033532"]}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PD\/BDE\/135076\/2017"],"award-info":[{"award-number":["PD\/BDE\/135076\/2017"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0716-8","type":"journal-article","created":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T14:04:26Z","timestamp":1567605866000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Biomaterial-based platforms for in situ dendritic cell programming and their use in antitumor immunotherapy"],"prefix":"10.1136","volume":"7","author":[{"given":"Jo\u00e3o","family":"Calmeiro","sequence":"first","affiliation":[]},{"given":"Myl\u00e8ne","family":"Carrascal","sequence":"additional","affiliation":[]},{"given":"C\u00e9lia","family":"Gomes","sequence":"additional","affiliation":[]},{"given":"Am\u00edlcar","family":"Falc\u00e3o","sequence":"additional","affiliation":[]},{"given":"Maria Teresa","family":"Cruz","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7391-3124","authenticated-orcid":false,"given":"Bruno Miguel","family":"Neves","sequence":"additional","affiliation":[]}],"member":"239","published-online":{"date-parts":[[2019,9,4]]},"reference":[{"key":"716_CR1","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1056\/NEJM197709012970907","volume":"297","author":"HF Oettgen","year":"1977","unstructured":"Oettgen HF. Immunotherapy of cancer. N Engl J Med. 1977;297:484\u201391.","journal-title":"N Engl J Med"},{"issue":"5","key":"716_CR2","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nrc.2018.6","volume":"18","author":"Wilfred Ngwa","year":"2018","unstructured":"Ngwa W, Irabor OC, Schoenfeld JD, Hesser J, Demaria S, Formenti SC. Using immunotherapy to boost the abscopal effect. Nat Rev Cancer. 2018;18:313\u201322.","journal-title":"Nature Reviews Cancer"},{"key":"716_CR3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ctrv.2017.01.008","volume":"54","author":"J Martin-Liberal","year":"2017","unstructured":"Martin-Liberal J, Ochoa de Olza M, Hierro C, Gros A, Rodon J, Tabernero J. The expanding role of immunotherapy. Cancer Treat Rev. 2017;54:74\u201386.","journal-title":"Cancer Treat Rev"},{"key":"716_CR4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.trsl.2015.07.008","volume":"168","author":"J Constantino","year":"2016","unstructured":"Constantino J, Gomes C, Falc\u00e3o A, Cruz MT, Neves BM. Antitumor dendritic cell-based vaccines: lessons from 20 years of clinical trials and future perspectives. Transl Res. 2016;168:74\u201395.","journal-title":"Transl Res"},{"key":"716_CR5","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.immuni.2013.07.004","volume":"39","author":"K Palucka","year":"2013","unstructured":"Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity. 2013;39:38\u201348.","journal-title":"Immunity."},{"key":"716_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1600-065X.2010.00979.x","volume":"239","author":"CA Klebanoff","year":"2011","unstructured":"Klebanoff CA, Acquavella N, Yu Z, Restifo NP. Therapeutic cancer vaccines: are we there yet? Immunol Rev. 2011;239:27.","journal-title":"Immunol Rev"},{"key":"716_CR7","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/nm1100","volume":"10","author":"SA Rosenberg","year":"2004","unstructured":"Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909\u201315.","journal-title":"Nat Med"},{"key":"716_CR8","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1016\/S1470-2045(13)70585-0","volume":"15","author":"S Anguille","year":"2014","unstructured":"Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN. Clinical use of dendritic cells for cancer therapy. Lancet Oncol. 2014;15:e257\u201367.","journal-title":"Lancet Oncol."},{"key":"716_CR9","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1200\/JCO.2012.43.7103","volume":"31","author":"J Vansteenkiste","year":"2013","unstructured":"Vansteenkiste J, Zielinski M, Linder A, Dahabreh J, Gonzalez EE, Malinowski W, et al. Adjuvant MAGE-A3 immunotherapy in resected non\u2013small-cell lung Cancer: phase II randomized study results. J Clin Oncol. 2013;31:2396\u2013403.","journal-title":"J Clin Oncol"},{"key":"716_CR10","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1200\/JCO.2012.43.7111","volume":"31","author":"WHJ Kruit","year":"2013","unstructured":"Kruit WHJ, Suciu S, Dreno B, Mortier L, Robert C, Chiarion-Sileni V, et al. Selection of Immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer melanoma Group in Metastatic Melanoma. J Clin Oncol. 2013;31:2413\u201320.","journal-title":"J Clin Oncol"},{"key":"716_CR11","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s00432-011-1003-3","volume":"137","author":"C Butts","year":"2011","unstructured":"Butts C, Maksymiuk A, Goss G, Souli\u00e8res D, Marshall E, Cormier Y, et al. Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. J Cancer Res Clin Oncol. 2011;137:1337\u201342.","journal-title":"J Cancer Res Clin Oncol"},{"key":"716_CR12","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S1470-2045(13)70510-2","volume":"15","author":"C Butts","year":"2014","unstructured":"Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15:59\u201368.","journal-title":"Lancet Oncol"},{"key":"716_CR13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.4292\/wjgpt.v7.i1.133","volume":"7","author":"M Okamoto","year":"2016","unstructured":"Okamoto M, Kobayashi M, Yonemitsu Y, Koido S, Homma S. Dendritic cell-based vaccine for pancreatic cancer in Japan. World J Gastrointest Pharmacol Ther. 2016;7:133.","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"716_CR14","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1158\/1078-0432.CCR-08-2729","volume":"15","author":"P Verdijk","year":"2009","unstructured":"Verdijk P, Aarntzen EHJG, Lesterhuis WJ, Boullart ACI, Kok E, van Rossum MM, et al. Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res. 2009;15:2531\u201340.","journal-title":"Clin Cancer Res"},{"key":"716_CR15","doi-asserted-by":"publisher","first-page":"4254","DOI":"10.4049\/jimmunol.166.6.4254","volume":"166","author":"L Fong","year":"2001","unstructured":"Fong L, Brockstedt D, Benike C, Wu L, Engleman EG. Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol. 2001;166:4254\u20139.","journal-title":"J Immunol"},{"key":"716_CR16","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1158\/1078-0432.CCR-10-3421","volume":"17","author":"E Romano","year":"2011","unstructured":"Romano E, Rossi M, Ratzinger G, de Cos M-A, Chung DJ, Panageas KS, et al. Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo. Clin Cancer Res. 2011;17:1984\u201397.","journal-title":"Clin Cancer Res"},{"key":"716_CR17","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.4049\/jimmunol.173.4.2780","volume":"173","author":"G Ratzinger","year":"2004","unstructured":"Ratzinger G, Baggers J, de Cos MA, Yuan J, Dao T, Reagan JL, et al. Mature human Langerhans cells derived from CD34+ hematopoietic progenitors stimulate greater cytolytic T lymphocyte activity in the absence of bioactive IL-12p70, by either single peptide presentation or cross-priming, than do dermal-interstitial or monoc. J Immunol. 2004;173:2780\u201391.","journal-title":"J Immunol"},{"key":"716_CR18","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1172\/JCI31205","volume":"117","author":"E Gilboa","year":"2007","unstructured":"Gilboa E. DC-based cancer vaccines. J Clin Invest. 2007;117:1195\u2013203.","journal-title":"J Clin Invest"},{"key":"716_CR19","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/nature06175","volume":"449","author":"RM Steinman","year":"2007","unstructured":"Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature. 2007;449:419\u201326.","journal-title":"Nature."},{"key":"716_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/fimmu.2012.00013","volume":"3","author":"I Caminschi","year":"2012","unstructured":"Caminschi I, Maraskovsky E, Heath WR. Targeting dendritic cells in vivo for Cancer therapy. Front Immunol. 2012;3:13.","journal-title":"Front Immunol"},{"key":"716_CR21","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3389\/fimmu.2014.00255","volume":"5","author":"L Cohn","year":"2014","unstructured":"Cohn L, Delamarre L. Dendritic cell-targeted vaccines. Front Immunol. 2014;5:255.","journal-title":"Front Immunol"},{"key":"716_CR22","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1084\/jem.20032220","volume":"199","author":"LC Bonifaz","year":"2004","unstructured":"Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S-I, Soares H, et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med. 2004;199:815\u201324.","journal-title":"J Exp Med"},{"key":"716_CR23","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/nri3727","volume":"14","author":"W Kastenm\u00fcller","year":"2014","unstructured":"Kastenm\u00fcller W, Kastenm\u00fcller K, Kurts C, Seder RA. Dendritic cell-targeted vaccines \u2014 hope or hype? Nat Rev Immunol. 2014;14:705\u201311.","journal-title":"Nat Rev Immunol"},{"key":"716_CR24","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1097\/CJI.0b013e318135472c","volume":"30","author":"A Kretz-Rommel","year":"2007","unstructured":"Kretz-Rommel A, Qin F, Dakappagari N, Torensma R, Faas S, Wu D, et al. In vivo targeting of antigens to human dendritic cells through DC-SIGN elicits stimulatory immune responses and inhibits tumor growth in grafted mouse models. J Immunother. 2007;30:715\u201326.","journal-title":"J Immunother"},{"key":"716_CR25","doi-asserted-by":"publisher","first-page":"e87102","DOI":"10.1172\/jci.insight.87102","volume":"1","author":"KM Tullett","year":"2016","unstructured":"Tullett KM, Leal Rojas IM, Minoda Y, Tan PS, Zhang J-G, Smith C, et al. Targeting CLEC9A delivers antigen to human CD141(+) DC for CD4(+) and CD8(+)T cell recognition. JCI insight. 2016;1:e87102.","journal-title":"JCI insight"},{"key":"716_CR26","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1182\/blood-2012-01-402370","volume":"120","author":"B Chatterjee","year":"2012","unstructured":"Chatterjee B, Smed-Sorensen A, Cohn L, Chalouni C, Vandlen R, Lee B-C, et al. Internalization and endosomal degradation of receptor-bound antigens regulate the efficiency of cross presentation by human dendritic cells. Blood. 2012;120:2011\u201320.","journal-title":"Blood."},{"key":"716_CR27","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.4049\/jimmunol.1300787","volume":"191","author":"J Tel","year":"2013","unstructured":"Tel J, Sittig SP, Blom RAM, Cruz LJ, Schreibelt G, Figdor CG, et al. Targeting uptake receptors on human Plasmacytoid dendritic cells triggers antigen cross-presentation and robust type I IFN secretion. J Immunol. 2013;191:5005\u201312.","journal-title":"J Immunol"},{"key":"716_CR28","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1002\/eji.201040790","volume":"41","author":"J Tel","year":"2011","unstructured":"Tel J, Benitez-Ribas D, Hoosemans S, Cambi A, Adema GJ, Figdor CG, et al. DEC-205 mediates antigen uptake and presentation by both resting and activated human plasmacytoid dendritic cells. Eur J Immunol. 2011;41:1014\u201323.","journal-title":"Eur J Immunol"},{"key":"716_CR29","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1084\/jem.20021598","volume":"196","author":"L Bonifaz","year":"2002","unstructured":"Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med. 2002;196:1627\u201338.","journal-title":"J Exp Med"},{"key":"716_CR30","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1073\/pnas.90.8.3539","volume":"90","author":"G Dranoff","year":"1993","unstructured":"Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A. 1993;90:3539\u201343.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"716_CR31","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0952-7915(00)00144-8","volume":"12","author":"N Mach","year":"2000","unstructured":"Mach N, Dranoff G. Cytokine-secreting tumor cell vaccines. Curr Opin Immunol. 2000;12:571\u20135.","journal-title":"Curr Opin Immunol"},{"key":"716_CR32","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2217\/imt-2016-0141","volume":"9","author":"W-L Yan","year":"2017","unstructured":"Yan W-L, Shen K-Y, Tien C-Y, Chen Y-A, Liu S-J. Recent progress in GM-CSF-based cancer immunotherapy. Immunotherapy. 2017;9:347\u201360.","journal-title":"Immunotherapy."},{"key":"716_CR33","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/nrc2843","volume":"10","author":"D Metcalf","year":"2010","unstructured":"Metcalf D. The colony-stimulating factors and cancer. Nat Rev Cancer. 2010;10:425\u201334.","journal-title":"Nat Rev Cancer"},{"key":"716_CR34","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1182\/blood-2007-03-079681","volume":"111","author":"D Metcalf","year":"2008","unstructured":"Metcalf D. Hematopoietic cytokines. Blood. 2008;111:485\u201391.","journal-title":"Blood."},{"key":"716_CR35","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1182\/blood-2008-12-164004","volume":"114","author":"TR Hercus","year":"2009","unstructured":"Hercus TR, Thomas D, Guthridge MA, Ekert PG, King-Scott J, Parker MW, et al. The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease. Blood. 2009;114:1289\u201398.","journal-title":"Blood."},{"key":"716_CR36","doi-asserted-by":"crossref","unstructured":"Bhattacharya P, Haddad C, Alharshawi K, Prabhakar B. The role of GM-CSF in dendritic cell development in vivo (HEM3P.284). J Immunol. 2014;192(1 Supplement):51.13.","DOI":"10.4049\/jimmunol.192.Supp.51.13"},{"key":"716_CR37","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1002\/eji.201242477","volume":"42","author":"Y Zhan","year":"2012","unstructured":"Zhan Y, Vega-Ramos J, Carrington EM, Villadangos JA, Lew AM, Xu Y. The inflammatory cytokine, GM-CSF, alters the developmental outcome of murine dendritic cells. Eur J Immunol. 2012;42:2889\u2013900.","journal-title":"Eur J Immunol"},{"key":"716_CR38","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1182\/blood-2011-11-370130","volume":"119","author":"L Laar van de","year":"2012","unstructured":"van de Laar L, Coffer PJ, Woltman AM. Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapy. Blood. 2012;119:3383\u201393.","journal-title":"Blood."},{"key":"716_CR39","first-page":"5334","volume":"49","author":"Y Yamashita","year":"1989","unstructured":"Yamashita Y, Nara N, Aoki N. Antiproliferative and differentiative effect of granulocyte-macrophage colony-stimulating factor on a variant human small cell lung cancer cell line. Cancer Res. 1989;49:5334\u20138.","journal-title":"Cancer Res"},{"key":"716_CR40","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1158\/0008-5472.CAN-12-0806","volume":"73","author":"RG Urdinguio","year":"2013","unstructured":"Urdinguio RG, Fernandez AF, Moncada-Pazos A, Huidobro C, Rodriguez RM, Ferrero C, et al. Immune-dependent and independent antitumor activity of GM-CSF aberrantly expressed by mouse and human colorectal tumors. Cancer Res. 2013;73:395\u2013405.","journal-title":"Cancer Res"},{"key":"716_CR41","doi-asserted-by":"publisher","first-page":"8ra19","DOI":"10.1126\/scitranslmed.3000359","volume":"1","author":"OA Ali","year":"2009","unstructured":"Ali OA, Emerich D, Dranoff G, Mooney DJ. In Situ Regulation of DC Subsets and T Cells Mediates Tumor Regression in Mice. Sci Transl Med. 2009;1:8ra19.","journal-title":"Sci Transl Med"},{"key":"716_CR42","doi-asserted-by":"publisher","first-page":"6658","DOI":"10.1182\/blood-2008-06-161075","volume":"113","author":"S Zarei","year":"2009","unstructured":"Zarei S, Schwenter F, Luy P, Aurrand-Lions M, Morel P, Kopf M, et al. Role of GM-CSF signaling in cell-based tumor immunization. Blood. 2009;113:6658\u201368.","journal-title":"Blood."},{"key":"716_CR43","first-page":"3239","volume":"60","author":"N Mach","year":"2000","unstructured":"Mach N, Gillessen S, Wilson SB, Sheehan C, Mihm M, Dranoff G. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage Colony-stimulating factor or Flt3-ligand 1. Cancer Res. 2000;60:3239\u201346.","journal-title":"Cancer Res"},{"key":"716_CR44","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s12967-015-0572-3","volume":"13","author":"EJ Lipson","year":"2015","unstructured":"Lipson EJ, Sharfman WH, Chen S, McMiller TL, Pritchard TS, Salas JT, et al. Safety and immunologic correlates of melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting. J Transl Med. 2015;13:214.","journal-title":"J Transl Med"},{"key":"716_CR45","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s002620100213","volume":"50","author":"M Kusumoto","year":"2001","unstructured":"Kusumoto M, Umeda S, Ikubo A, Aoki Y, Tawfik O, Oben R, et al. Phase 1 clinical trial of irradiated autologous melanoma cells adenovirally transduced with human GM-CSF gene. Cancer Immunol Immunother. 2001;50:373\u201381.","journal-title":"Cancer Immunol Immunother"},{"key":"716_CR46","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1158\/2326-6066.CIR-14-0027","volume":"2","author":"ER Lutz","year":"2014","unstructured":"Lutz ER, Wu AA, Bigelow E, Sharma R, Mo G, Soares K, et al. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol Res. 2014;2:616\u201331.","journal-title":"Cancer Immunol Res."},{"key":"716_CR47","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1158\/1078-0432.CCR-07-0371","volume":"14","author":"D Laheru","year":"2008","unstructured":"Laheru D, Lutz E, Burke J, Biedrzycki B, Solt S, Onners B, et al. Allogeneic granulocyte macrophage Colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic Cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res. 2008;14:1455\u201363.","journal-title":"Clin Cancer Res"},{"key":"716_CR48","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1097\/SLA.0b013e3181fd271c","volume":"253","author":"E Lutz","year":"2011","unstructured":"Lutz E, Yeo CJ, Lillemoe KD, Biedrzycki B, Kobrin B, Herman J, et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A phase II trial of safety, efficacy, and immune activation. Ann Surg. 2011;253:328\u201335.","journal-title":"Ann Surg"},{"key":"716_CR49","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/cncr.23669","volume":"113","author":"CS Higano","year":"2008","unstructured":"Higano CS, Corman JM, Smith DC, Centeno AS, Steidle CP, Gittleman M, et al. Phase 1\/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer. 2008;113:975\u201384.","journal-title":"Cancer."},{"key":"716_CR50","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1097\/PPO.0b013e3181eb33d7","volume":"16","author":"DT Le","year":"2010","unstructured":"Le DT, Pardoll DM, Jaffee EM. Cellular vaccine approaches. Cancer J. 2010;16:304\u201310.","journal-title":"Cancer J"},{"key":"716_CR51","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.ymthe.2004.07.001","volume":"10","author":"K Tani","year":"2004","unstructured":"Tani K, Azuma M, Nakazaki Y, Oyaizu N, Hase H, Ohata J, et al. Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell Cancer in Japan: clinical and immunological findings. Mol Ther. 2004;10:799\u2013816.","journal-title":"Mol Ther"},{"key":"716_CR52","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1158\/1078-0432.CCR-09-2046","volume":"16","author":"BD Smith","year":"2010","unstructured":"Smith BD, Kasamon YL, Kowalski J, Gocke C, Murphy K, Miller CB, et al. K562\/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res. 2010;16:338\u201347.","journal-title":"Clin Cancer Res"},{"key":"716_CR53","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1200\/JCO.2006.08.5829","volume":"25","author":"P Filipazzi","year":"2007","unstructured":"Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol. 2007;25:2546\u201353.","journal-title":"J Clin Oncol"},{"key":"716_CR54","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1172\/JCI31422","volume":"117","author":"A Sica","year":"2007","unstructured":"Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest. 2007;117:1155\u201366.","journal-title":"J Clin Invest"},{"key":"716_CR55","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1111\/j.1349-7006.2009.01202.x","volume":"100","author":"M Jinushi","year":"2009","unstructured":"Jinushi M, Tahara H. Cytokine gene-mediated immunotherapy: current status and future perspectives. Cancer Sci. 2009;100:1389\u201396.","journal-title":"Cancer Sci"},{"key":"716_CR56","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nrclinonc.2014.111","volume":"11","author":"I Melero","year":"2014","unstructured":"Melero I, Gaudernack G, Gerritsen W, Huber C, Parmiani G, Scholl S, et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol. 2014;11:509\u201324.","journal-title":"Nat Rev Clin Oncol"},{"key":"716_CR57","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2217\/14796694.5.2.187","volume":"5","author":"PM Arlen","year":"2009","unstructured":"Arlen PM, Mohebtash M, Madan RA, Gulley JL. Promising novel immunotherapies and combinations for prostate cancer. Future Oncol. 2009;5:187\u201396.","journal-title":"Future Oncol"},{"key":"716_CR58","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ejpb.2017.03.013","volume":"115","author":"X Zang","year":"2017","unstructured":"Zang X, Zhao X, Hu H, Qiao M, Deng Y, Chen D. Nanoparticles for tumor immunotherapy. Eur J Pharm Biopharm. 2017;115:243\u201356.","journal-title":"Eur J Pharm Biopharm"},{"key":"716_CR59","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0168-3659(02)00275-4","volume":"85","author":"M Diwan","year":"2002","unstructured":"Diwan M, Tafaghodi M, Samuel J. Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres. J Control Release. 2002;85:247\u201362.","journal-title":"J Control Release"},{"key":"716_CR60","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.nano.2010.03.001","volume":"6","author":"C Clawson","year":"2010","unstructured":"Clawson C, Huang C-T, Futalan D, Martin Seible D, Saenz R, Larsson M, et al. Delivery of a peptide via poly(d,l-lactic-co-glycolic) acid nanoparticles enhances its dendritic cell\u2013stimulatory capacity. Nanomed Nanotechnol Biol Med. 2010;6:651\u201361.","journal-title":"Nanomed Nanotechnol Biol Med"},{"key":"716_CR61","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/nbt0102-64","volume":"20","author":"T Kumamoto","year":"2002","unstructured":"Kumamoto T, Huang EK, Paek HJ, Morita A, Matsue H, Valentini RF, et al. Induction of tumor-specific protective immunity by in situ Langerhans cell vaccine. Nat Biotechnol. 2002;20:64\u20139.","journal-title":"Nat Biotechnol"},{"key":"716_CR62","doi-asserted-by":"publisher","first-page":"3836","DOI":"10.1021\/bm501166j","volume":"15","author":"Y Liu","year":"2014","unstructured":"Liu Y, Xiao L, Joo K-I, Hu B, Fang J, Wang P. In situ modulation of dendritic cells by injectable thermosensitive hydrogels for cancer vaccines in mice. Biomacromolecules. 2014;15:3836\u201345.","journal-title":"Biomacromolecules."},{"key":"716_CR63","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/nmat2357","volume":"8","author":"OA Ali","year":"2009","unstructured":"Ali OA, Huebsch N, Cao L, Dranoff G, Mooney DJ. Infection-mimicking materials to program dendritic cells in situ. Nat Mater. 2009;8:151\u20138.","journal-title":"Nat Mater"},{"key":"716_CR64","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1158\/0008-5472.CAN-13-0777","volume":"74","author":"OA Ali","year":"2014","unstructured":"Ali OA, Verbeke C, Johnson C, Sands RW, Lewin SA, White D, et al. Identification of immune factors regulating antitumor immunity using polymeric vaccines with multiple adjuvants. Cancer Res. 2014;74:1670\u201381.","journal-title":"Cancer Res"},{"key":"716_CR65","doi-asserted-by":"publisher","first-page":"66","DOI":"10.4161\/biom.1.1.16277","volume":"1","author":"OA Ali","year":"2011","unstructured":"Ali OA, Doherty E, Mooney DJ, Emerich D. Relationship of vaccine efficacy to the kinetics of DC and T-cell responses induced by PLG-based cancer vaccines. Biomatter. 2011;1:66\u201375.","journal-title":"Biomatter."},{"key":"716_CR66","doi-asserted-by":"publisher","first-page":"4621","DOI":"10.1002\/adfm.201203859","volume":"23","author":"OA Ali","year":"2013","unstructured":"Ali OA, Tayalia P, Shvartsman D, Lewin S, Mooney DJ. Inflammatory cytokines presented from polymer matrices differentially generate and activate DCs in situ. Adv Funct Mater. 2013;23:4621\u20138.","journal-title":"Adv Funct Mater"},{"key":"716_CR67","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1007\/s11095-010-0361-x","volume":"28","author":"OA Ali","year":"2011","unstructured":"Ali OA, Doherty E, Bell WJ, Fradet T, Hudak J, Laliberte M-T, et al. Biomaterial-based vaccine induces regression of established intracranial glioma in rats. Pharm Res. 2011;28:1074\u201380.","journal-title":"Pharm Res"},{"key":"716_CR68","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jconrel.2011.06.021","volume":"154","author":"OA Ali","year":"2011","unstructured":"Ali OA, Doherty E, Bell WJ, Fradet T, Hudak J, Laliberte M-T, et al. The efficacy of intracranial PLG-based vaccines is dependent on direct implantation into brain tissue. J Control Release. 2011;154:249\u201357.","journal-title":"J Control Release"},{"key":"716_CR69","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1158\/2326-6066.CIR-14-0126","volume":"4","author":"OA Ali","year":"2016","unstructured":"Ali OA, Lewin SA, Dranoff G, Mooney DJ. Vaccines combined with immune checkpoint antibodies promote cytotoxic T-cell activity and tumor eradication. Cancer Immunol Res. 2016;4:95\u2013100.","journal-title":"Cancer Immunol Res"},{"key":"716_CR70","doi-asserted-by":"crossref","unstructured":"Bencherif S, Draganov D, Lewin S, Li A, Sands R, Verbeke C, et al. Immunologically active cryogels for breast cancer therapy (P4329). J Immunol. 2013;190(1 Supplement):126.1.","DOI":"10.4049\/jimmunol.190.Supp.126.1"},{"key":"716_CR71","doi-asserted-by":"publisher","first-page":"7556","DOI":"10.1038\/ncomms8556","volume":"6","author":"SA Bencherif","year":"2015","unstructured":"Bencherif SA, Warren Sands R, Ali OA, Li WA, Lewin SA, Braschler TM, et al. Injectable cryogel-based whole-cell cancer vaccines. Nat Commun. 2015;6:7556.","journal-title":"Nat Commun"},{"key":"716_CR72","doi-asserted-by":"publisher","first-page":"1701469","DOI":"10.1002\/adhm.201701469","volume":"7","author":"T-Y Shih","year":"2018","unstructured":"Shih T-Y, Blacklow SO, Li AW, Freedman BR, Bencherif S, Koshy ST, et al. Injectable, Tough Alginate Cryogels as Cancer Vaccines. Adv Healthc Mater. 2018;7:1701469.","journal-title":"Adv Healthc Mater"},{"key":"716_CR73","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jconrel.2011.06.008","volume":"155","author":"A Singh","year":"2011","unstructured":"Singh A, Qin H, Fernandez I, Wei J, Lin J, Kwak LW, et al. An injectable synthetic immune-priming center mediates efficient T-cell class switching and T-helper 1 response against B cell lymphoma. J Control Release. 2011;155:184\u201392.","journal-title":"J Control Release"},{"key":"716_CR74","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/nbt.3071","volume":"33","author":"J Kim","year":"2014","unstructured":"Kim J, Li WA, Choi Y, Lewin SA, Verbeke CS, Dranoff G, et al. Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy. Nat Biotechnol. 2014;33:64\u201372.","journal-title":"Nat Biotechnol"},{"key":"716_CR75","doi-asserted-by":"publisher","first-page":"5227","DOI":"10.1016\/j.biomaterials.2010.03.027","volume":"31","author":"K-T Peng","year":"2010","unstructured":"Peng K-T, Chen C-F, Chu I-M, Li Y-M, Hsu W-H, Hsu RW-W, et al. Treatment of osteomyelitis with teicoplanin-encapsulated biodegradable thermosensitive hydrogel nanoparticles. Biomaterials. 2010;31:5227\u201336.","journal-title":"Biomaterials."},{"key":"716_CR76","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.3390\/ijms15033640","volume":"15","author":"P Gentile","year":"2014","unstructured":"Gentile P, Chiono V, Carmagnola I, Hatton PV. An overview of poly(lactic-co-glycolic) acid (PLGA)-based biomaterials for bone tissue engineering. Int J Mol Sci. 2014;15:3640\u201359.","journal-title":"Int J Mol Sci"},{"key":"716_CR77","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/0142-9612(96)87284-X","volume":"17","author":"DJ Mooney","year":"1996","unstructured":"Mooney DJ, Baldwin DF, Suh NP, Vacanti JP, Langer R. Novel approach to fabricate porous sponges of poly(D,L-lactic-co-glycolic acid) without the use of organic solvents. Biomaterials. 1996;17:1417\u201322.","journal-title":"Biomaterials."},{"key":"716_CR78","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/(SICI)1097-4636(19981205)42:3<396::AID-JBM7>3.0.CO;2-E","volume":"42","author":"LD Harris","year":"1998","unstructured":"Harris LD, Kim BS, Mooney DJ. Open pore biodegradable matrices formed with gas foaming. J Biomed Mater Res. 1998;42:396\u2013402.","journal-title":"J Biomed Mater Res"},{"key":"716_CR79","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1016\/j.biomaterials.2008.05.033","volume":"29","author":"Y Hori","year":"2008","unstructured":"Hori Y, Winans AM, Huang CC, Horrigan EM, Irvine DJ. Injectable dendritic cell-carrying alginate gels for immunization and immunotherapy. Biomaterials. 2008;29:3671\u201382.","journal-title":"Biomaterials."},{"key":"716_CR80","doi-asserted-by":"publisher","first-page":"19590","DOI":"10.1073\/pnas.1211516109","volume":"109","author":"SA Bencherif","year":"2012","unstructured":"Bencherif SA, Sands RW, Bhatta D, Arany P, Verbeke CS, Edwards DA, et al. Injectable preformed scaffolds with shape-memory properties. Proc Natl Acad Sci U S A. 2012;109:19590\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"716_CR81","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1016\/j.biomaterials.2009.06.001","volume":"30","author":"A Singh","year":"2009","unstructured":"Singh A, Suri S, Roy K. In-situ crosslinking hydrogels for combinatorial delivery of chemokines and siRNA\u2013DNA carrying microparticles to dendritic cells. Biomaterials. 2009;30:5187\u2013200.","journal-title":"Biomaterials."},{"key":"716_CR82","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1016\/j.biomaterials.2013.11.044","volume":"35","author":"ST Koshy","year":"2014","unstructured":"Koshy ST, Ferrante TC, Lewin SA, Mooney DJ. Injectable, porous, and cell-responsive gelatin cryogels. Biomaterials. 2014;35:2477\u201387.","journal-title":"Biomaterials."},{"key":"716_CR83","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1089\/ten.teb.2007.0332","volume":"14","author":"GD Nicodemus","year":"2008","unstructured":"Nicodemus GD, Bryant SJ. Cell encapsulation in biodegradable hydrogels for tissue engineering applications. Tissue Eng Part B Rev. 2008;14:149\u201365.","journal-title":"Tissue Eng Part B Rev"},{"key":"716_CR84","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.addr.2007.03.013","volume":"59","author":"JD Kretlow","year":"2007","unstructured":"Kretlow JD, Klouda L, Mikos AG. Injectable matrices and scaffolds for drug delivery in tissue engineering. Adv Drug Deliv Rev. 2007;59:263\u201373.","journal-title":"Adv Drug Deliv Rev"},{"key":"716_CR85","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.polymer.2008.01.027","volume":"49","author":"R Todd","year":"2008","unstructured":"Todd R, Hoare DSK. Hydrogels in drug delivery: Progress and challenges. Polymer (Guildf). 2008;49:1993\u20132007.","journal-title":"Polymer (Guildf)"},{"key":"716_CR86","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ijpharm.2015.01.013","volume":"479","author":"CV Kulkarni","year":"2015","unstructured":"Kulkarni CV, Moinuddin Z, Patil-Sen Y, Littlefield R, Hood M. Lipid-hydrogel films for sustained drug release. Int J Pharm. 2015;479:416\u201321.","journal-title":"Int J Pharm"},{"key":"716_CR87","doi-asserted-by":"publisher","first-page":"7097","DOI":"10.1039\/C5PY01204J","volume":"6","author":"W Zhu","year":"2015","unstructured":"Zhu W, Xiong L, Wang H, Zha G, Du H, Li X, et al. Sustained drug release from an ultrathin hydrogel film. Polym Chem. 2015;6:7097\u20139.","journal-title":"Polym Chem"},{"key":"716_CR88","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1021\/cr200157d","volume":"112","author":"T Vermonden","year":"2012","unstructured":"Vermonden T, Censi R, Hennink WE. Hydrogels for Protein Delivery. Chem Rev. 2012;112:2853\u201388.","journal-title":"Chem Rev"},{"key":"716_CR89","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1039\/B917142H","volume":"20","author":"Y Hwang","year":"2010","unstructured":"Hwang Y, Zhang C, Varghese S. Poly(ethylene glycol) cryogels as potential cell scaffolds: effect of polymerization conditions on cryogel microstructure and properties. J Mater Chem. 2010;20:345\u201351.","journal-title":"J Mater Chem"},{"key":"716_CR90","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.tibtech.2003.08.002","volume":"21","author":"VI Lozinsky","year":"2003","unstructured":"Lozinsky VI, Galaev IY, Plieva FM, Savina IN, Jungvid H, Mattiasson B. Polymeric cryogels as promising materials of biotechnological interest. Trends Biotechnol. 2003;21:445\u201351.","journal-title":"Trends Biotechnol"},{"key":"716_CR91","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1039\/c3tb20280a","volume":"1","author":"TMA Henderson","year":"2013","unstructured":"Henderson TMA, Ladewig K, Haylock DN, McLean KM, O\u2019Connor AJ. Cryogels for biomedical applications. J Mater Chem B. 2013;1:2682.","journal-title":"J Mater Chem B"},{"key":"716_CR92","doi-asserted-by":"crossref","unstructured":"Reichelt S. Introduction to Macroporous Cryogels. Methods Mol Biol. 2015;1286:173\u201381.","DOI":"10.1007\/978-1-4939-2447-9_14"},{"key":"716_CR93","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1369-7021(10)70202-9","volume":"13","author":"A Kumar","year":"2010","unstructured":"Kumar A, YRSB RM. Cryogels: Freezing unveiled by thawing. Mater Today. 2010;13:42\u20134.","journal-title":"Mater Today"},{"key":"716_CR94","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/bab.46","volume":"58","author":"N Akbar","year":"2011","unstructured":"Akbar N, Mohamed T, Whitehead D, Azzawi M. Biocompatibility of amorphous silica nanoparticles: size and charge effect on vascular function, in vitro. Biotechnol Appl Biochem. 2011;58:353\u201362.","journal-title":"Biotechnol Appl Biochem"},{"key":"716_CR95","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1872-0854(10)04007-5","volume":"4","author":"A Petushkov","year":"2010","unstructured":"Petushkov A, Ndiege N, Salem AK, Larsen S. Toxicity of silica nanomaterials: zeolites, mesoporous silica, and amorphous silica nanoparticles. Adv Mol Toxicol. 2010;4:223\u201366.","journal-title":"Adv Mol Toxicol"},{"key":"716_CR96","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1007\/s00204-016-1850-4","volume":"90","author":"C Fruijtier-P\u00f6lloth","year":"2016","unstructured":"Fruijtier-P\u00f6lloth C. The safety of nanostructured synthetic amorphous silica (SAS) as a food additive (E 551). Arch Toxicol. 2016;90:2885\u2013916.","journal-title":"Arch Toxicol"},{"key":"716_CR97","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1021\/nn900918w","volume":"3","author":"T Xia","year":"2009","unstructured":"Xia T, Kovochich M, Liong M, Meng H, Kabehie S, George S, et al. Polyethyleneimine coating enhances the cellular uptake of mesoporous silica nanoparticles and allows safe delivery of siRNA and DNA constructs. ACS Nano. 2009;3:3273\u201386.","journal-title":"ACS Nano"},{"key":"716_CR98","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1039\/c1cs15246g","volume":"41","author":"Z Li","year":"2012","unstructured":"Li Z, Barnes JC, Bosoy A, Stoddart JF, Zink JI. Mesoporous silica nanoparticles in biomedical applications. Chem Soc Rev. 2012;41:2590.","journal-title":"Chem Soc Rev"},{"key":"716_CR99","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/(SICI)1521-4095(199903)11:4<303::AID-ADMA303>3.0.CO;2-M","volume":"11","author":"P Schmidt-Winkel","year":"1999","unstructured":"Schmidt-Winkel P, Yang P, Margolese DI, Chmelka BF, Stucky GD. Fluoride-induced hierarchical ordering of mesoporous silica in aqueous acid-syntheses. Adv Mater. 1999;11:303\u20137.","journal-title":"Adv Mater"},{"key":"716_CR100","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1021\/la902144h","volume":"26","author":"A Sundblom","year":"2010","unstructured":"Sundblom A, Palmqvist AEC, Holmberg K. Study of the Pluronic\u2212silica interaction in synthesis of mesoporous silica under mild acidic conditions. Langmuir. 2010;26:1983\u201390.","journal-title":"Langmuir."},{"key":"716_CR101","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.micromeso.2004.06.021","volume":"74","author":"A Marco","year":"2004","unstructured":"Marco A, Martines U, Yeong E, Andr\u00e9 Larbot EP. Temperature dependence in the synthesis of hexagonal MSU-3 type mesoporous silica synthesized with Pluronic P123 block copolymer. Microporous Mesoporous Mater. 2004;74:213\u201320.","journal-title":"Microporous Mesoporous Mater"},{"key":"716_CR102","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.biomaterials.2016.01.026","volume":"83","author":"WA Li","year":"2016","unstructured":"Li WA, Lu BY, Gu L, Choi Y, Kim J, Mooney DJ. The effect of surface modification of mesoporous silica micro-rod scaffold on immune cell activation and infiltration. Biomaterials. 2016;83:249\u201356.","journal-title":"Biomaterials."},{"key":"716_CR103","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1084\/jem.20100348","volume":"207","author":"A Bachem","year":"2010","unstructured":"Bachem A, G\u00fcttler S, Hartung E, Ebstein F, Schaefer M, Tannert A, et al. Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells. J Exp Med. 2010;207:1273\u201381.","journal-title":"J Exp Med"},{"key":"716_CR104","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s00262-008-0563-9","volume":"58","author":"V Flacher","year":"2009","unstructured":"Flacher V, Sparber F, Tripp CH, Romani N, Stoitzner P. Targeting of epidermal Langerhans cells with antigenic proteins: attempts to harness their properties for immunotherapy. Cancer Immunol Immunother. 2009;58:1137\u201347.","journal-title":"Cancer Immunol Immunother"},{"key":"716_CR105","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.immuni.2008.07.013","volume":"29","author":"E Klechevsky","year":"2008","unstructured":"Klechevsky E, Morita R, Liu M, Cao Y, Coquery S, Thompson-Snipes L, et al. Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity. 2008;29:497\u2013510.","journal-title":"Immunity."},{"key":"716_CR106","first-page":"9","volume":"10","author":"J-C Cancel","year":"2019","unstructured":"Cancel J-C, Crozat K, Dalod M, Mattiuz R. Are conventional type 1 dendritic cells critical for protective antitumor immunity and how? Front Immunol. Frontiers. 2019;10:9.","journal-title":"Frontiers"},{"key":"716_CR107","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.immuni.2009.08.027","volume":"31","author":"BG Dorner","year":"2009","unstructured":"Dorner BG, Dorner MB, Zhou X, Opitz C, Mora A, G\u00fcttler S, et al. Selective expression of the chemokine receptor XCR1 on cross-presenting dendritic cells determines cooperation with CD8+ T cells. Immunity. 2009;31:823\u201333.","journal-title":"Immunity."},{"key":"716_CR108","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3389\/fimmu.2019.00294","volume":"10","author":"NK Botelho","year":"2019","unstructured":"Botelho NK, Tschumi BO, Hubbell JA, Swartz MA, Donda A, Romero P. Combination of synthetic long peptides and XCL1 fusion proteins results in superior tumor control. Front Immunol. 2019;10:294.","journal-title":"Front Immunol"},{"key":"716_CR109","doi-asserted-by":"publisher","first-page":"5895","DOI":"10.4049\/jimmunol.1500564","volume":"194","author":"D Terhorst","year":"2015","unstructured":"Terhorst D, Fossum E, Baranska A, Tamoutounour S, Malosse C, Garbani M, et al. Laser-assisted intradermal delivery of adjuvant-free vaccines targeting XCR1 + dendritic cells induces potent Antitumoral responses. J Immunol. 2015;194:5895\u2013902.","journal-title":"J Immunol"},{"key":"716_CR110","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1126\/science.aaf7447","volume":"357","author":"KJ McHugh","year":"2017","unstructured":"McHugh KJ, Nguyen TD, Linehan AR, Yang D, Behrens AM, Rose S, et al. Fabrication of fillable microparticles and other complex 3D microstructures. Science. 2017;357:1138\u201342.","journal-title":"Science."},{"key":"716_CR111","unstructured":"Wang R-F, Wang HY. Immune targets and neoantigens for cancer immunotherapy and precision medicine. Cell Res Publ online 27 December 2016; | doi: 101038\/cr2016155. Nat Publ Group; 2016;27:11."},{"key":"716_CR112","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan N, Furness AJS, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351:1463\u20139.","journal-title":"Science"},{"key":"716_CR113","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348:69\u201374.","journal-title":"Science"},{"key":"716_CR114","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","volume":"547","author":"U Sahin","year":"2017","unstructured":"Sahin U, Derhovanessian E, Miller M, Kloke B-P, Simon P, L\u00f6wer M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547:222\u20136.","journal-title":"Nature"},{"key":"716_CR115","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547:217\u201321.","journal-title":"Nature"},{"key":"716_CR116","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1021\/acsnano.7b00978","volume":"11","author":"G Zhu","year":"2017","unstructured":"Zhu G, Zhang F, Ni Q, Niu G, Chen X. Efficient Nanovaccine delivery in Cancer immunotherapy. ACS Nano. 2017;11:2387\u201392.","journal-title":"ACS Nano"},{"key":"716_CR117","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1126\/science.aaa3828","volume":"348","author":"BM Carreno","year":"2015","unstructured":"Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, et al. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 2015;348:803\u20138.","journal-title":"Science"},{"key":"716_CR118","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nmat4822","volume":"16","author":"R Kuai","year":"2017","unstructured":"Kuai R, Ochyl LJ, Bahjat KS, Schwendeman A, Moon JJ. Designer vaccine nanodiscs for personalized cancer immunotherapy. Nat Mater. 2017;16:489\u201398.","journal-title":"Nat Mater"},{"key":"716_CR119","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1038\/s41467-017-01386-7","volume":"8","author":"G Zhu","year":"2017","unstructured":"Zhu G, Mei L, Vishwasrao HD, Jacobson O, Wang Z, Liu Y, et al. Intertwining DNA-RNA nanocapsules loaded with tumor neoantigens as synergistic nanovaccines for cancer immunotherapy. Nat Commun. 2017;8:1482.","journal-title":"Nat Commun"},{"key":"716_CR120","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/s41563-018-0028-2","volume":"17","author":"AW Li","year":"2018","unstructured":"Li AW, Sobral MC, Badrinath S, Choi Y, Graveline A, Stafford AG, et al. A facile approach to enhance antigen response for personalized cancer vaccination. Nat Mater. 2018;17:528\u201334.","journal-title":"Nat Mater"},{"key":"716_CR121","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1111\/cas.12695","volume":"106","author":"K Adachi","year":"2015","unstructured":"Adachi K, Tamada K. Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. Cancer Sci. 2015;106:945\u201350.","journal-title":"Cancer Sci"},{"key":"716_CR122","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to Cancer therapy. Cancer Cell. 2015;27:450\u201361.","journal-title":"Cancer Cell"},{"key":"716_CR123","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41551-018-0250-x","volume":"2","author":"M Saxena","year":"2018","unstructured":"Saxena M, Balan S, Roudko V, Bhardwaj N. Towards superior dendritic-cell vaccines for cancer therapy. Nat Biomed Eng. 2018;2:341\u20136.","journal-title":"Nat Biomed Eng"},{"key":"716_CR124","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/ITT.S122497","volume":"6","author":"M Scholz","year":"2017","unstructured":"Scholz M, Yep S, Chancey M, Kelly C, Chau K, Turner J, et al. Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer. ImmunoTargets Ther. 2017;6:11\u20136.","journal-title":"ImmunoTargets Ther"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0716-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0716-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0716-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T21:10:34Z","timestamp":1695157834000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0716-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,4]]},"references-count":124,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["716"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0716-8","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,4]]},"assertion":[{"value":"24 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"238"}}